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Biomarker-guided antibiotic use in primary care in 
resource-constrained environments
Because of antimicrobial resistance, the global overuse 
of antibiotics is now a threat to one of the most eﬀ ective 
and mortality-lowering interventions in modern 
medicine.1 One of the most important challenges is to 
substantially lower the use of antibiotics when these 
drugs are not needed. The fear of missing a severe case 
of pneumonia can incit e health-care providers to ignore 
the fact that, in many non-severe cases of respiratory 
tract infections, antibiotic treatment will probably 
not markedly alter the outcome for the individual 
patient.2 Reduction of antibiotic use will require reliable 
and broadly applicable segregation of non-bacterial 
infection and trivial bacterial infections from serious 
bacterial infections.
In The Lancet Global Health, Nga Do and colleagues3 
report the results of a large (more than 2000 participants) 
randomised controlled trial of a point-of-care antibiotic 
strategy guided by C-reactive protein concentrations 
compared with usual best practice in primary care 
patients with non-severe acute respiratory tract infection 
in Vietnam. The results demonstrate that a point-of-care 
C-reactive protein intervention can reduce antibiotic 
prescribing in this setting, albeit with only a moderate 
reduction in absolute risk (adjusted 12·5%; intervention 
64·4% vs control 77·9%). Importantly, there were no 
apparent diﬀ erences in serious adverse eﬀ ects or delayed 
patient recovery.
Do and colleagues should be congratulated on 
completing this ambitious, large-scale trial to assess 
a point-of-care biomarker-guided antibiotic strategy 
in a resource-constrained environment. The results 
expand the current evidence base by showing that 
such a stewardship approach is applicable in low-
income and middle-income countries. Furthermore, 
Do and colleagues performed a very sensitive sample 
size calculation to prove the trial robust for subgroup 
analysis in children. The eﬀ ect size was similar to adults. 
The results support the ﬁ ndings from randomised 
trials in Europe, summarised in a 2014 Cochrane review,4 
which found C-reactive protein eﬀ ective in reducing 
antibiotic use with no apparent risk to patient safety. 
So, why was the eﬀ ect of the current approach only 
moderate? Some limitations to the study should be 
mentioned. First, the cut-oﬀ  applied in the current study 
(10 mg/L in children younger than 6 years, 20 mg/L in 
all other patients) is low, allowing for antibiotic use in 
many low-risk patients and patients without bacterial 
infection. Second, overruling of the algorithm was 
very common; in fact, 88% of all C-reactive protein 
measurements were below 20 mg/L and thus the 
potential to reduce antibiotic use seems much higher 
than the actual numbers in the current study. In order to 
improve the eﬀ ect size we should start looking at ways 
to optimise use of this tool. 
Undoubtedly, part of this optimisation comes down to 
issues of public health and cultural habits among both 
patients and physicians. Physicians should be trained 
to adhere to the algorithm to a much larger extent. 
Improved education and associated increased adherence 
to the algorithm could lead to further reductions in 
antibiotic use, as can be read from the large degree 
of heterogeneity detected (I²=84%) corresponding to 
diﬀ erences in eﬀ ect size among sites, which is a speciﬁ c 
concern and limitation of the current study. Previous 
studies have shown that education in communicative 
skills works well together with point-of-care C-reactive 
protein testing.5,6 It has also been shown that doctors 
that do not understand a speciﬁ c strategy well use it 
poorly.7
Arguably, many of these patients should not have a 
C-reactive protein test done in the ﬁ rst place. Only non-
severe infections were included, thus increasing the 
risk of spectrum bias. Biomarker tests should ideally be 
used to rule out a high risk of severe infection when the 
provider is uncertain if antibiotic prescribing is likely 
to be beneﬁ cial, and to negotiate a perceived strong 
patient demand for an antibiotic prescription.
Future trials in settings like the current should consider 
increasing the cutoﬀ  for no antibiotic therapy. If the 
patient is in no acute distress, with a C-reactive protein 
level below 50 mg/L, a serious bacterial infection is 
rarely present. Alternatively, all cases of acute respiratory 
tract infections that do not need urgent admission to 
hospital could be included.4,5,8 
However, reduction of antimicrobial resistance 
cannot be achieved merely by the introduction of a 
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single test. Access to education, the promotion of a 
change of behavioural norms, vaccination coverage, 
and other preventive measures must work in concert 
to preserve antibiotic eﬃ  cacy. Regulatory authorities 
need to consider the vast self-purchase of antibiotics 
(eg, in Vietnam around 90% of prescriptions are self-
purchased)9 and legislate to prevent this bypass of proper 
medical control of over-the-counter sales.
Implementation of antibiotic stewardship strategies 
often awaits proof of cost-eﬀ ectiveness.10 This con-
vention must be challenged: we are facing a problem 
of a magnitude that urges us to implement eﬀ ective 
strategies even if they are marginally more expensive. 
The rise in antimicrobial resistance suggests that short-
term savings of the current strategy could be vastly 
outweighed by future costs for hospital treatment 
of otherwise trivial infections with highly resistant 
infectious pathogens.11 
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